Last updated on December 2018

A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis


Brief description of study

This is a double-blind, randomized, 8 week, vehicle-controlled efficacy and safety study of Ruxolitinib cream followed by a long-term safety extension period in adolescents and adults with atopic dermatitis (eczema).

All enrolled subjects will receive a topical medication to be applied daily for 8 weeks. There are 9 in office visits throughout the study which may include a physical exam, blood draws, urine sampling, assessments by qualified professionals and other assessments which will be reviewed in detail at your screening visit.

At the end of the 8 week study period, participants will have the option to continue receiving treatment in a long-term extension study. All services are provided at no cost.

 

Detailed Study Description

  • Physical exam and assessments of study condition to be provided at no cost by an experienced provider.
  • No insurance necessary.
  • Compensation will be provided at the end of study participation.

 

Clinical Study Identifier: TX217809

Contact Investigators or Research Sites near you

Start Over

Kerry Castellon

Sadick Research Group
New York, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.